Loading…
Loading…
it's a smidge surprising you didn't guide for maybe a little more growth at that line. Was there any pull forward of demand
Can you just describe the M&A environment and your readiness and your priorities to potentially get a little more aggressive
is there an argument that even though you talked about 100 basis points of margin expansion potential next year
Have you seen any change in activity over the last few weeks or even just -- even in the tone of discussions
you had previously told us to expect high single-digit bioprocessing revenue growth for the year. Is that still the case
I just want to make sure this is a continuation of trend and not really anything new in terms of a further deterioration
this implies kind of what's embedded into your guidance, is an implied 5% core and normalized diagnostic growth rate
So it's hard for a stock to work, when the estimates keep moving in the wrong direction
I'm curious what you're seeing in terms of movement towards reshoring in the US
you have to at least contemplate a scenario where the market growth rate is structurally lower
are you expecting to exit 2025 back in your targeted 7% to 9% organic growth range